Up-to-date clinical approaches of biomarkers’ use in heart failure
DOI:
https://doi.org/10.15419/bmrat.v4i06.178Keywords:
Biomarker guided-therapy, Biomarkers, Heart failure, Prediction, StratificationAbstract
Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients’ population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.
References
Abdalrhim, A.D., Marroush, T.S., Austin, E.E., Gersh, B.J., Solak, N., Rizvi, S.A., Bailey, K.R., and Kullo, I.J. (2016). Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial. PloS one 11, e0156965.
AbouEzzeddine, O.F., McKie, P.M., Dunlay, S.M., Stevens, S.R., Felker, G.M., Borlaug, B.A., Chen, H.H., Tracy, R.P., Braunwald, E., and Redfield, M.M. (2017). Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association 6, e004382.
Agnello, L., Bivona, G., Sasso, B.L., Scazzone, C., Bazan, V., Bellia, C., and Ciaccio, M. (2017). Galectin-3 in acute coronary syndrome. Clinical Biochemistry S0009-9120, 30245-X.
Aimo, A., Vergaro, G., Ripoli, A., Bayes-Genis, A., Figal, D.A.P., de Boer, R.A., Lassus, J., Mebazaa, A., Gayat, E., and Breidthardt, T. (2017). Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure 5, 287-296.
Alford, A.I., and Hankenson, K.D. (2006). Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 38, 749-757.
Amin, A., Chitsazan, M., Shiukhi Ahmad Abad, F., Taghavi, S., and Naderi, N. (2017). On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. ESC Heart Failure 4, 162-168.
Anguita, M. (2017). High-sensitivity troponins and prognosis of heart failure. Revista clinica espanola 217, 95-96.
Ara-Somohano, C., Bonadona, A., Carpentier, F., Pavese, P., Vesin, A., Hamidfar-Roy, R., Minet, C., Vanzetto, G., Schwebel, C., and Timsit, J. (2017). Evaluation of eight biomarkers to predict short term mortality in patients with acute severe dyspnea. Minerva anestesiologica, 10.23736/S20375-29393.23717.10882-23735.
Aspromonte, N., Gulizia, M., Clerico, A., Di Tano, G., Emdin, M., Feola, M., Iacoviello, M., Latini, R., Mortara, A., and Valle, R. (2016). ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients. Giornale italiano di cardiologia (2006) 17, 615.
Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., Zamora, E., Urrutia, A., and Lupón, J. (2014). Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology 63, 158-166.
Bayes-Genis, A., and Ordonez-Llanos, J. (2015). Multiple biomarker strategies for risk stratification in heart failure. Clinica Chimica Acta 443, 120-125.
Berezin (2015a). The Myeloid-Related Protein Complex Calprotectin as Biomarker of Cardiovascular Risk in Diabetes Mellitus Patients. Diabetes Res Treat, 129-136.
Berezin (2015b). Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. (Moskow: LAMBERT Academic Publishing GmbH).
Berezin (2016a). Genetic Predictive Scores in Heart Failure: Possibilities and Expectations. J Data Mining Genomics Proteomics 7, e127-e128.
Berezin, A. (2014). Serum uric acid as a metabolic regulator of endothelial reparative processes in heart failure patients. Stem Cell and Translational Investigation 1, e432.
Berezin, A. (2015c). Impaired pattern of endothelial derived microparticles in heart failure patients. J Mol Genet Med 9, 2380-0682.
Berezin, A. (2016b). Biomarkers for cardiovascular risk in diabetic patients. Heart 102, 1939-1941.
Berezin, A. (2016c). Epigenetics in heart failure phenotypes. BBA Clin 6, 31-37.
Berezin, A., and Kremzer, A. (2013a). Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229, 475-481.
Berezin, A., and Kremzer, A. (2013b). Serum uric Acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiology research and practice 2013, 129369.
Berezin, A.E. (2007). Endothelial derived micro particles: biomarkers for heart failure diagnosis and management. Br J Haematol 137, 36-48.
Berezin, A.E. (2015d). Biomarker-Guided Therapy for Chronic Heart Failure. In Biomarkers in Cardiovascular Disease, V.B. Patel, and V.R. Preedy, eds. (Dordrecht: Springer Netherlands), pp. 1-21.
Berezin, A.E. (2015e). Bone-Related Proteins as Markers in Vascular Remodeling. In Biomarkers in Bone Disease, V.R. Preedy, ed. (Springer), pp. 1-22.
Berezin, A.E. (2015f). The risk stratification in heart failure patients: The controversial role of high-sensitive ST2. inflammation 411, 20-27.
Berezin, A.E. (2016d). Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 10, S154-S157.
Berezin, A.E. (2016e). Epigenetically Modified Endothelial Progenitor Cells in Heart Failure. Journal of Clinical Epigenetics 2, 13.
Berezin, A.E. (2016f). Prognostication in different heart failure phenotypes: the role of circulating biomarkers. Journal of Circulating Biomarkers 5, 6.
Berezin, A.E., and Kremzer, A.A. (2013c). Analysis of various subsets of circulating mononuclear cells in asymptomatic coronary artery disease. Journal of clinical medicine 2, 32-44.
Berezin, A.E., and Kremzer, A.A. (2014a). Predictive Value of Circulating SPARC-Related protein Osteonectin in Patients with Symptomatic Moderate-to-Severe Ischemic-Induced Chronic Heart Failure. International Journal of Cardiology and Lipidology Research 1, 43-51.
Berezin, A.E., and Kremzer, A.A. (2014b). Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8, 138-144.
Berezin, A.E., and Kremzer, A.A. (2014c). Relationship between serum RANKL/osteoprotegerin complex and endothelial progenitor cells in ischemic chronic heart failure. Journal of Cardiology and Therapy 1, 189-195.
Berezin, A.E., and Kremzer, A.A. (2015). Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure. Biomedical Journal 38, 523-530.
Berezin, A.E., Kremzer, A.A., Berezina, T.A., and Martovitskaya, Y.V. (2015a). Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA clinical 4, 69-75.
Berezin, A.E., Kremzer, A.A., Berezina, T.A., Martovitskaya, Y.V., and Gromenko, E.A. (2016a). Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. Biomedical Research and Therapy 3, 501-513.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Berezina, T.A., and Samura, T.A. (2016b). The utility of biomarker risk prediction score in patients with chronic heart failure. Clinical hypertension 22, 3.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., and Berezina, T.A. (2015b). The predictive role of circulating microparticles in patients with chronic heart failure. BBA clinical 3, 18-24.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., Berezina, T.A., Zulli, A., Klimas, J., and Kruzliak, P. (2015c). The utility of biomarker risk prediction score in patients with chronic heart failure. International journal of clinical and experimental medicine 8, 18255-18264.
Berezin, A.E., Kremzer, A.A., and Samura, T.A. (2016c). Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease. Journal of biomedical research 30, 32.
Berezin, A.E., Kremzer, A.A., Samura, T.A., Berezina, T.A., and Martovitskaya, Y.V. (2014a). Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. Journal of cardiovascular and thoracic research 6, 153.
Berezin, A.E., Kremzer, A.A., Samura, T.A., and Martovitskaya, Y.V. (2014b). Apoptotic microparticles to progenitor mononuclear cells ratio in heart failure: relevance of clinical status and outcomes. JCvD 2, 50-57.
Berezin, A.E., and Samura, T.A. (2013). Prognostic value of biological markers in myocardial infarction patients. Asian Cardiovascular and Thoracic Annals 21, 142-150.
Besler, C., Lang, D., Urban, D., Rommel, K.-P., von Roeder, M., Fengler, K., Blazek, S., Kandolf, R., Klingel, K., and Thiele, H. (2017). Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis. Circulation: Heart Failure 10, e003804.
Billebeau, G., Vodovar, N., Sadoune, M., Launay, J.M., Beauvais, F., and Cohen-Solal, A. (2017). Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur J Prev Cardiol, 2047487317705488.
Bondar, G., Cadeiras, M., Wisniewski, N., Maque, J., Chittoor, J., Chang, E., Bakir, M., Starling, C., Shahzad, K., Ping, P., et al. (2014). Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure. PloS one 9, e115097.
Borghi, C., Rosei, E.A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J.T., Manolis, A.J., Perez-Ruiz, F., and Mancia, G. (2015). Serum uric acid and the risk of cardiovascular and renal disease. Journal of hypertension 33, 1729-1741.
Boulogne, M., Sadoune, M., Launay, J., Baudet, M., Cohen-Solal, A., and Logeart, D. (2017). Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. International Journal of Cardiology 226, 53-59.
Bruhn, L.V., Lauridsen, K.G., Schmidt, A.S., Rickers, H., Bach, L.F., Løfgren, B., and Hornung, N. (2017). Elevated calprotectin in patients with atrial fibrillation with and without heart failure. Scandinavian Journal of Clinical and Laboratory Investigation 77, 210-215.
Cabiati, M., Svezia, B., Matteucci, M., Botta, L., Pucci, A., Rinaldi, M., Caselli, C., Lionetti, V., and Del Ry, S. (2016). Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy. PloS one 11, e0160110.
Chan, M.M., Santhanakrishnan, R., Chong, J.P., Chen, Z., Tai, B.C., Liew, O.W., Ng, T.P., Ling, L.H., Sim, D., and Leong, K.T.G. (2016). Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. European journal of heart failure 18, 81-88.
Chmurzyńska, A. (2006). The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. Journal of applied genetics 47, 39-48.
Chow, S.L., Maisel, A.S., Anand, I., Bozkurt, B., de Boer, R.A., Felker, G.M., Fonarow, G.C., Greenberg, B., Januzzi, J.L., Jr., Kiernan, M.S., et al. (2017). Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation 135, e1054-e1091.
Cohen-Solal, A., Laribi, S., Ishihara, S., Vergaro, G., Baudet, M., Logeart, D., Mebazaa, A., Gayat, E., Vodovar, N., Pascual-Figal, D.A., et al. (2015). Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Archives of cardiovascular diseases 108, 64-74.
Collier, P., Watson, C.J., Voon, V., Phelan, D., Jan, A., Mak, G., Martos, R., Baugh, J.A., Ledwidge, M.T., and McDonald, K.M. (2011). Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? European journal of heart failure 13, 1087-1095.
de Freitas Souza, B.S., Silva, D.N., Carvalho, R.H., de Almeida Sampaio, G.L., Paredes, B.D., França, L.A., Azevedo, C.M., Vasconcelos, J.F., Meira, C.S., and Neto, P.C. (2017). Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. The American Journal of Pathology 187, 1134-1146.
Demissei, B.G., Cotter, G., Prescott, M.F., Felker, G.M., Filippatos, G., Greenberg, B.H., Pang, P.S., Ponikowski, P., Severin, T.M., and Wang, Y. (2017). A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial. European Journal of Heart Failure, 10.1002/ejhf.1749.
Favresse, J., and Gruson, D. (2017). Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. Paper presented at: Annales de Biologie Clinique.
Fazakas, Á., Szelényi, Z., Szénási, G., Nyírő, G., Szabó, P.M., Patócs, A., Tegze, N., Fekete, B.C., Molvarec, A., and Nagy, B. (2016). Genetic predisposition in patients with hypertension and normal ejection fraction to oxidative stress. Journal of the American Society of Hypertension 10, 124-132.
Friedrich, F.W., Dilanian, G., Khattar, P., Juhr, D., Gueneau, L., Charron, P., Fressart, V., Vilquin, J.T., Isnard, R., and Gouya, L. (2013). A novel genetic variant in the transcription factor Islet‐1 exerts gain of function on myocyte enhancer factor 2C promoter activity. European journal of heart failure 15, 267-276.
Ganna, A., Rivadeneira, F., Hofman, A., Uitterlinden, A.G., Magnusson, P.K., Pedersen, N.L., Ingelsson, E., and Tiemeier, H. (2013). Genetic determinants of mortality. Can findings from genome-wide association studies explain variation in human mortality? Human genetics 132, 553-561.
Grassi, D., Ferri, L., Desideri, G., Di Giosia, P., Cheli, P., Del Pinto, R., Properzi, G., and Ferri, C. (2013). Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Current pharmaceutical design 19, 2432-2438.
Hage, C., Michaëlsson, E., Linde, C., Donal, E., Daubert, J.-C., Gan, L.-M., and Lund, L.H. (2017). Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Genetics 10, e001633.
Hayashida, K., Kondo, Y., Hara, Y., Aihara, M., and Yamakawa, K. (2017). Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis. BMJ open 7, e014305.
Hershberger, R.E., and Siegfried, J.D. (2011). Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57, 1641-1649.
Hofman, N., van Langen, I., and Wilde, A.A. (2010). Genetic testing in cardiovascular diseases. Current opinion in cardiology 25, 243-248.
Huerta, A., López, B., Ravassa, S., San José, G., Querejeta, R., Beloqui, Ó., Zubillaga, E., Rábago, G., Brugnolaro, C., and Díez, J. (2016). Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. Journal of hypertension 34, 130-138.
Hutchinson, K.R., Stewart, J.A., and Lucchesi, P.A. (2010). Extracellular matrix remodeling during the progression of volume overload-induced heart failure. Journal of molecular and cellular cardiology 48, 564-569.
Imran, T.F., Shin, H.J., Mathenge, N., Wang, F., Kim, B., Joseph, J., Gaziano, J.M., and Djoussé, L. (2017). Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. The American Journal of Cardiology 119, 57-64.
Jansen, F., Nickenig, G., and Werner, N. (2017). Extracellular Vesicles in Cardiovascular Disease. Circulation research 120, 1649-1657.
Kang, S., Fan, L., Chen, M., Li, J., and Liu, Z. (2017). Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure. Current vascular pharmacology, 10.2174/1570161115666170404121619.
Kempf, T., and Wollert, K.C. (2009). Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34, 594-599.
Kim, H., Yoon, H.J., Park, H.S., Cho, Y.K., Nam, C.W., Hur, S.H., Kim, Y.N., and Kim, K.B. (2013). Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congestive Heart Failure 19, 123-129.
Kim, T.-H., Kim, H., and Kim, I.-C. (2015). The potential of cystatin-C to evaluate the prognosis of acute heart failure: A comparative study. Acute Cardiac Care 17, 72-76.
Kitai, T., Kim, Y.-H., Kiefer, K., Morales, R., Borowski, A.G., Grodin, J.L., and Tang, W.W. (2017). Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clinical Biochemistry 50, 491-495.
Kolder, I.C., Michels, M., Christiaans, I., Ten Cate, F.J., Majoor-Krakauer, D., Danser, A.H., Lekanne Deprez, R.H., Tanck, M., Wilde, A.A., Bezzina, C.R., et al. (2012). The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. European journal of human genetics : EJHG 20, 1071-1077.
Krane, V., Genser, B., Kleber, M.E., Drechsler, C., März, W., Delgado, G., Allolio, B., Wanner, C., and Fenske, W. (2017). Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study. Clinical Chemistry 63, 997-1007.
Krintus, M., Kozinski, M., Fabiszak, T., Kubica, J., Panteghini, M., and Sypniewska, G. (2017). Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry 50, 599-604.
Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., and Patle, A. (2013). Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. Jama 310, 66-74.
Li, J., Yousefi, K., Ding, W., Singh, J., and Shehadeh, L.A. (2017). Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure. Cardiovascular research 113, 633-643.
Löfsjögård, J., Kahan, T., Díez, J., López, B., González, A., Ravassa, S., Mejhert, M., Edner, M., and Persson, H. (2017). Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients≥ 60 Years With Heart Failure and Reduced Ejection Fraction. The American Journal of Cardiology 119, 2042-2048.
Löfsjögård, J., Persson, H., Díez, J., López, B., González, A., Edner, M., Mejhert, M., and Kahan, T. (2014). Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. Scandinavian Cardiovascular Journal 48, 299-303.
Lopes, L.R., and Elliott, P.M. (2013). Genetics of heart failure. Biochimica et biophysica acta 1832, 2451-2461.
Luchner, A., Von Haehling, S., Holubarsch, C., Keller, T., Knebel, F., Zugck, C., and Laufs, U. (2017). Indications and Clinical Implications of the Use of the Cardiac Markers BNP and NT-proBNP. Deutsche medizinische Wochenschrift (1946) 142, 346.
Maisel, A.S., and Di Somma, S. (2016). Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). European Heart Journal, ehw462.
Malek, V., and Gaikwad, A.B. (2017). Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 90, 752-759.
Masson, S., Latini, R., and Anand, I.S. (2010). An update on cardiac troponins as circulating biomarkers in heart failure. Current heart failure reports 7, 15-21.
McNamara, D.M., Taylor, A.L., Tam, S.W., Worcel, M., Yancy, C.W., Hanley-Yanez, K., Cohn, J.N., and Feldman, A.M. (2014). G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. JACC: Heart Failure 2, 551-557.
Meijers, W.C., van der Velde, A.R., Muller Kobold, A.C., Dijck‐Brouwer, J., Wu, A.H., Jaffe, A., and de Boer, R.A. (2016). Variability of biomarkers in patients with chronic heart failure and healthy controls. European Journal of Heart Failure 19, 357-365.
Miró, Ò., González de la Presa, B., Herrero-Puente, P., Fernández Bonifacio, R., Möckel, M., Mueller, C., Casals, G., Sandalinas, S., Llorens, P., and Martín-Sánchez, F.J. (2017). The GALA study: relationship between galectin-3 serum levels and short-and long-term outcomes of patients with acute heart failure. Biomarkers, 10.1080/1354750X.1352017.1319421.
Moayedi, Y., and Ross, H.J. (2017). Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clinical science (London, England : 1979) 131, 553-566.
Morgenthaler, N.G., Struck, J., Alonso, C., and Bergmann, A. (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical chemistry 52, 112-119.
Nagarajan, V., Hernandez, A.V., and Tang, W.W. (2012). Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart, heartjnl-2012-301779.
Nakanishi, M., Nakao, K., Kumasaka, L., Arakawa, T., Fukui, S., Ohara, T., Yanase, M., Noguchi, T., Yasuda, S., and Goto, Y. (2017). Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level. Circulation Journal, CJ-16-1268.
Nelveg-Kristensen, K.E., Busk Madsen, M., Torp-Pedersen, C., Kober, L., Egfjord, M., Berg Rasmussen, H., and Riis Hansen, P. (2015). Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study. PloS one 10, e0144195.
Nymo, S.H., Aukrust, P., Kjekshus, J., McMurray, J.J., Cleland, J.G., Wikstrand, J., Muntendam, P., Wienhues-Thelen, U., Latini, R., Askevold, E.T., et al. (2017). Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. JACC Heart failure 5, 256-264.
Okazaki, H., Shirakabe, A., Kobayashi, N., Hata, N., Shinada, T., Matsushita, M., Yamamoto, Y., Shibata, Y., Shibuya, J., Shiomura, R., et al. (2017). Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart and Vessels 32, 436-445.
Okazaki, H., Shirakabe, A., Kobayashi, N., Hata, N., Shinada, T., Matsushita, M., Yamamoto, Y., Shibuya, J., Shiomura, R., and Nishigoori, S. (2016). The prognostic impact of uric acid in patients with severely decompensated acute heart failure. Journal of cardiology 68, 384-391.
Otaki, Y., Watanabe, T., Kinoshita, D., Yokoyama, M., Takahashi, T., Toshima, T., Sugai, T., Murase, T., Nakamura, T., and Nishiyama, S. (2017). Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. International Journal of Cardiology 228, 151-157.
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., Falk, V., González-Juanatey, J.R., Harjola, V.-P., and Jankowska, E.A. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal 37, 2129-2200.
Pouleur, A.-C. (2015). Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? Clinica Chimica Acta 443, 9-16.
Puente, P.H., García, B.P., García, M.G., Jacob, J., Martín-Sánchez, F.J., Pascual-Figal, D., Bueno, H., Gil, V., Llorens, P., and Vázquez-Alvarez, J. (2017). Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency department for acute heart failure. BIO-EAHFE study. Clinica Chimica Acta 466, 22-30.
Qian, H.-Y., Huang, J., Yang, Y.-J., Yang, Y.-M., Li, Z.-Z., and Zhang, J.-M. (2016). Heart-type Fatty Acid Binding Protein in the Assessment of Acute Pulmonary Embolism. The American Journal of the Medical Sciences 352, 557-562.
Reiner, M.M., Khoury, W.E., Canales, M.B., Chmielewski, R.A., Patel, K., Razzante, M.C., Cloughtery, C.O., and Rowland, D.Y. (2017). Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections. The Journal of Foot and Ankle Surgery 56, 484-491.
Remde, H., Dietz, A., Emeny, R., Riester, A., Peters, A., de Las Heras Gala, T., Then, C., Seissler, J., Beuschlein, F., Reincke, M., et al. (2016). The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. Journal of hypertension 34, 2066-2073.
Rienks, M., and Papageorgiou, A.-P. (2016). Novel regulators of cardiac inflammation: matricellular proteins expand their repertoire. Journal of molecular and cellular cardiology 91, 172-178.
Ryu, J.A., Yang, J.H., Lee, D., Park, C.M., Suh, G.Y., Jeon, K., Cho, J., Baek, S.Y., Carriere, K.C., and Chung, C.R. (2015). Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock. PloS one 10, e0138150.
Sahin, I., Gungor, B., Ozkaynak, B., Uzun, F., Küçük, S.H., Avci, I.I., Ozal, E., Ayça, B., Cetın, S., and Okuyan, E. (2016). Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy. Clinical Cardiology 40, 32-37.
Sakamuri, S.S., Takawale, A., Basu, R., Fedak, P.W., Freed, D., Sergi, C., Oudit, G.Y., and Kassiri, Z. (2016). Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure. Translational Research 172, 30-44.
Savic-Radojevic, A., Pljesa-Ercegovac, M., Matic, M., Simic, D., Radovanovic, S., and Simic, T. (2017). Chapter Four-Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry 79, 93-152.
Simon, L., Gauvin, F., Amre, D.K., Saint-Louis, P., and Lacroix, J. (2004). Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clinical infectious diseases 39, 206-217.
Smaradottir, M.I., Ritsinger, V., Gyberg, V., Norhammar, A., Näsman, P., and Mellbin, L.G. (2017). Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities–A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research 14, 69-76.
Srivatsan, V., George, M., and Shanmugam, E. (2015). Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? European journal of preventive cardiology 22, 1096-1110.
Sutter, M.E., Gaedigk, A., Albertson, T.E., Southard, J., Owen, K.P., Mills, L.D., and Diercks, D.B. (2013). Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clinical toxicology (Philadelphia, Pa) 51, 540-544.
Taub, P.R., Borden, K.C., Fard, A., and Maisel, A. (2012). Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert review of cardiovascular therapy 10, 657-667.
Teekakirikul, P., Kelly, M.A., Rehm, H.L., Lakdawala, N.K., and Funke, B.H. (2013). Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. The Journal of Molecular Diagnostics 15, 158-170.
Teo, L.Y.L., Moran, R.T., and Tang, W.W. (2015). Evolving approaches to genetic evaluation of specific cardiomyopathies. Current heart failure reports 12, 339-349.
Tromp, J., Khan, M.A., Klip, I.T., Meyer, S., de Boer, R.A., Jaarsma, T., Hillege, H., van Veldhuisen, D.J., van der Meer, P., and Voors, A.A. (2017). Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American Heart Association 6, e003989.
Tziakas, D.N., Chalikias, G.K., Stakos, D., Chatzikyriakou, S.V., Papazoglou, D., Mitrousi, K., Lantzouraki, A., Thomaidi, A., Boudoulas, H., and Konstantinides, S. (2012). Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. European journal of preventive cardiology 19, 62-71.
Valiente-Alandi, I., Schafer, A.E., and Blaxall, B.C. (2016). Extracellular matrix-mediated cellular communication in the heart. Journal of molecular and cellular cardiology 91, 228-237.
Wettersten, N., and Maisel, A.S. (2016). Biomarkers for heart failure: An update for practitioners of internal medicine. The American journal of medicine 129, 560-567.
Wojciechowska, C., Romuk, E., Nowalany-Kozielska, E., and Jacheć, W. (2017). Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic Journal of Cardiology S1109-9666, 30249-30244.
Wong, P.C., Guo, J., and Zhang, A. (2017). The renal and cardiovascular effects of natriuretic peptides. Advances in physiology education 41, 179-185.
Wu, C.K., Luo, J.L., Tsai, C.T., Huang, Y.T., Cheng, C.L., Lee, J.K., Lin, L.Y., Lin, J.W., Hwang, J.J., and Chiang, F.T. (2010). Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The pharmacogenomics journal 10, 46-53.
Wu, C.K., Luo, J.L., Wu, X.M., Tsai, C.T., Lin, J.W., Hwang, J.J., Lin, J.L., Tseng, C.D., and Chiang, F.T. (2009). A propensity score-based case-control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. Atherosclerosis 205, 497-502.
Yan, J.J., Lu, Y., Kuai, Z.P., and Yong, Y.H. (2017). Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta‐analysis. Journal of Cellular and Molecular Medicine, 10.1111/jcmm.13102.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Jr., Colvin, M.M., Drazner, M.H., Filippatos, G.S., Fonarow, G.C., Givertz, M.M., et al. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of cardiac failure, 10.1016/j.cardfail.2017.1004.1014.
Yang, J., Xu, W.W., and Hu, S.J. (2015). Heart failure: advanced development in genetics and epigenetics. BioMed research international 2015, 352734.
Yip, V.L., and Pirmohamed, M. (2013). Expanding role of pharmacogenomics in the management of cardiovascular disorders. American journal of cardiovascular drugs : drugs, devices, and other interventions 13, 151-162.
Yu, B., Zheng, Y., Alexander, D., Manolio, T.A., Alonso, A., Nettleton, J.A., and Boerwinkle, E. (2013). Genome-wide association study of a heart failure related metabolomic profile among African Americans in the Atherosclerosis Risk in Communities (ARIC) study. Genetic epidemiology 37, 840-845.
Zhu, L., Zou, Y., Wang, Y., Luo, X., Sun, K., Wang, H., Jia, L., Liu, Y., Zou, J., and Yuan, Z. (2017). Prognostic Significance of Plasma High‐Sensitivity C‐Reactive Protein in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association 6, e004529.
AbouEzzeddine, O.F., McKie, P.M., Dunlay, S.M., Stevens, S.R., Felker, G.M., Borlaug, B.A., Chen, H.H., Tracy, R.P., Braunwald, E., and Redfield, M.M. (2017). Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association 6, e004382.
Agnello, L., Bivona, G., Sasso, B.L., Scazzone, C., Bazan, V., Bellia, C., and Ciaccio, M. (2017). Galectin-3 in acute coronary syndrome. Clinical Biochemistry S0009-9120, 30245-X.
Aimo, A., Vergaro, G., Ripoli, A., Bayes-Genis, A., Figal, D.A.P., de Boer, R.A., Lassus, J., Mebazaa, A., Gayat, E., and Breidthardt, T. (2017). Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure 5, 287-296.
Alford, A.I., and Hankenson, K.D. (2006). Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 38, 749-757.
Amin, A., Chitsazan, M., Shiukhi Ahmad Abad, F., Taghavi, S., and Naderi, N. (2017). On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. ESC Heart Failure 4, 162-168.
Anguita, M. (2017). High-sensitivity troponins and prognosis of heart failure. Revista clinica espanola 217, 95-96.
Ara-Somohano, C., Bonadona, A., Carpentier, F., Pavese, P., Vesin, A., Hamidfar-Roy, R., Minet, C., Vanzetto, G., Schwebel, C., and Timsit, J. (2017). Evaluation of eight biomarkers to predict short term mortality in patients with acute severe dyspnea. Minerva anestesiologica, 10.23736/S20375-29393.23717.10882-23735.
Aspromonte, N., Gulizia, M., Clerico, A., Di Tano, G., Emdin, M., Feola, M., Iacoviello, M., Latini, R., Mortara, A., and Valle, R. (2016). ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients. Giornale italiano di cardiologia (2006) 17, 615.
Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., Zamora, E., Urrutia, A., and Lupón, J. (2014). Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology 63, 158-166.
Bayes-Genis, A., and Ordonez-Llanos, J. (2015). Multiple biomarker strategies for risk stratification in heart failure. Clinica Chimica Acta 443, 120-125.
Berezin (2015a). The Myeloid-Related Protein Complex Calprotectin as Biomarker of Cardiovascular Risk in Diabetes Mellitus Patients. Diabetes Res Treat, 129-136.
Berezin (2015b). Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. (Moskow: LAMBERT Academic Publishing GmbH).
Berezin (2016a). Genetic Predictive Scores in Heart Failure: Possibilities and Expectations. J Data Mining Genomics Proteomics 7, e127-e128.
Berezin, A. (2014). Serum uric acid as a metabolic regulator of endothelial reparative processes in heart failure patients. Stem Cell and Translational Investigation 1, e432.
Berezin, A. (2015c). Impaired pattern of endothelial derived microparticles in heart failure patients. J Mol Genet Med 9, 2380-0682.
Berezin, A. (2016b). Biomarkers for cardiovascular risk in diabetic patients. Heart 102, 1939-1941.
Berezin, A. (2016c). Epigenetics in heart failure phenotypes. BBA Clin 6, 31-37.
Berezin, A., and Kremzer, A. (2013a). Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229, 475-481.
Berezin, A., and Kremzer, A. (2013b). Serum uric Acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiology research and practice 2013, 129369.
Berezin, A.E. (2007). Endothelial derived micro particles: biomarkers for heart failure diagnosis and management. Br J Haematol 137, 36-48.
Berezin, A.E. (2015d). Biomarker-Guided Therapy for Chronic Heart Failure. In Biomarkers in Cardiovascular Disease, V.B. Patel, and V.R. Preedy, eds. (Dordrecht: Springer Netherlands), pp. 1-21.
Berezin, A.E. (2015e). Bone-Related Proteins as Markers in Vascular Remodeling. In Biomarkers in Bone Disease, V.R. Preedy, ed. (Springer), pp. 1-22.
Berezin, A.E. (2015f). The risk stratification in heart failure patients: The controversial role of high-sensitive ST2. inflammation 411, 20-27.
Berezin, A.E. (2016d). Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 10, S154-S157.
Berezin, A.E. (2016e). Epigenetically Modified Endothelial Progenitor Cells in Heart Failure. Journal of Clinical Epigenetics 2, 13.
Berezin, A.E. (2016f). Prognostication in different heart failure phenotypes: the role of circulating biomarkers. Journal of Circulating Biomarkers 5, 6.
Berezin, A.E., and Kremzer, A.A. (2013c). Analysis of various subsets of circulating mononuclear cells in asymptomatic coronary artery disease. Journal of clinical medicine 2, 32-44.
Berezin, A.E., and Kremzer, A.A. (2014a). Predictive Value of Circulating SPARC-Related protein Osteonectin in Patients with Symptomatic Moderate-to-Severe Ischemic-Induced Chronic Heart Failure. International Journal of Cardiology and Lipidology Research 1, 43-51.
Berezin, A.E., and Kremzer, A.A. (2014b). Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8, 138-144.
Berezin, A.E., and Kremzer, A.A. (2014c). Relationship between serum RANKL/osteoprotegerin complex and endothelial progenitor cells in ischemic chronic heart failure. Journal of Cardiology and Therapy 1, 189-195.
Berezin, A.E., and Kremzer, A.A. (2015). Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure. Biomedical Journal 38, 523-530.
Berezin, A.E., Kremzer, A.A., Berezina, T.A., and Martovitskaya, Y.V. (2015a). Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA clinical 4, 69-75.
Berezin, A.E., Kremzer, A.A., Berezina, T.A., Martovitskaya, Y.V., and Gromenko, E.A. (2016a). Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. Biomedical Research and Therapy 3, 501-513.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Berezina, T.A., and Samura, T.A. (2016b). The utility of biomarker risk prediction score in patients with chronic heart failure. Clinical hypertension 22, 3.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., and Berezina, T.A. (2015b). The predictive role of circulating microparticles in patients with chronic heart failure. BBA clinical 3, 18-24.
Berezin, A.E., Kremzer, A.A., Martovitskaya, Y.V., Samura, T.A., Berezina, T.A., Zulli, A., Klimas, J., and Kruzliak, P. (2015c). The utility of biomarker risk prediction score in patients with chronic heart failure. International journal of clinical and experimental medicine 8, 18255-18264.
Berezin, A.E., Kremzer, A.A., and Samura, T.A. (2016c). Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease. Journal of biomedical research 30, 32.
Berezin, A.E., Kremzer, A.A., Samura, T.A., Berezina, T.A., and Martovitskaya, Y.V. (2014a). Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. Journal of cardiovascular and thoracic research 6, 153.
Berezin, A.E., Kremzer, A.A., Samura, T.A., and Martovitskaya, Y.V. (2014b). Apoptotic microparticles to progenitor mononuclear cells ratio in heart failure: relevance of clinical status and outcomes. JCvD 2, 50-57.
Berezin, A.E., and Samura, T.A. (2013). Prognostic value of biological markers in myocardial infarction patients. Asian Cardiovascular and Thoracic Annals 21, 142-150.
Besler, C., Lang, D., Urban, D., Rommel, K.-P., von Roeder, M., Fengler, K., Blazek, S., Kandolf, R., Klingel, K., and Thiele, H. (2017). Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis. Circulation: Heart Failure 10, e003804.
Billebeau, G., Vodovar, N., Sadoune, M., Launay, J.M., Beauvais, F., and Cohen-Solal, A. (2017). Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur J Prev Cardiol, 2047487317705488.
Bondar, G., Cadeiras, M., Wisniewski, N., Maque, J., Chittoor, J., Chang, E., Bakir, M., Starling, C., Shahzad, K., Ping, P., et al. (2014). Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure. PloS one 9, e115097.
Borghi, C., Rosei, E.A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J.T., Manolis, A.J., Perez-Ruiz, F., and Mancia, G. (2015). Serum uric acid and the risk of cardiovascular and renal disease. Journal of hypertension 33, 1729-1741.
Boulogne, M., Sadoune, M., Launay, J., Baudet, M., Cohen-Solal, A., and Logeart, D. (2017). Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. International Journal of Cardiology 226, 53-59.
Bruhn, L.V., Lauridsen, K.G., Schmidt, A.S., Rickers, H., Bach, L.F., Løfgren, B., and Hornung, N. (2017). Elevated calprotectin in patients with atrial fibrillation with and without heart failure. Scandinavian Journal of Clinical and Laboratory Investigation 77, 210-215.
Cabiati, M., Svezia, B., Matteucci, M., Botta, L., Pucci, A., Rinaldi, M., Caselli, C., Lionetti, V., and Del Ry, S. (2016). Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy. PloS one 11, e0160110.
Chan, M.M., Santhanakrishnan, R., Chong, J.P., Chen, Z., Tai, B.C., Liew, O.W., Ng, T.P., Ling, L.H., Sim, D., and Leong, K.T.G. (2016). Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. European journal of heart failure 18, 81-88.
Chmurzyńska, A. (2006). The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. Journal of applied genetics 47, 39-48.
Chow, S.L., Maisel, A.S., Anand, I., Bozkurt, B., de Boer, R.A., Felker, G.M., Fonarow, G.C., Greenberg, B., Januzzi, J.L., Jr., Kiernan, M.S., et al. (2017). Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation 135, e1054-e1091.
Cohen-Solal, A., Laribi, S., Ishihara, S., Vergaro, G., Baudet, M., Logeart, D., Mebazaa, A., Gayat, E., Vodovar, N., Pascual-Figal, D.A., et al. (2015). Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Archives of cardiovascular diseases 108, 64-74.
Collier, P., Watson, C.J., Voon, V., Phelan, D., Jan, A., Mak, G., Martos, R., Baugh, J.A., Ledwidge, M.T., and McDonald, K.M. (2011). Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? European journal of heart failure 13, 1087-1095.
de Freitas Souza, B.S., Silva, D.N., Carvalho, R.H., de Almeida Sampaio, G.L., Paredes, B.D., França, L.A., Azevedo, C.M., Vasconcelos, J.F., Meira, C.S., and Neto, P.C. (2017). Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. The American Journal of Pathology 187, 1134-1146.
Demissei, B.G., Cotter, G., Prescott, M.F., Felker, G.M., Filippatos, G., Greenberg, B.H., Pang, P.S., Ponikowski, P., Severin, T.M., and Wang, Y. (2017). A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial. European Journal of Heart Failure, 10.1002/ejhf.1749.
Favresse, J., and Gruson, D. (2017). Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. Paper presented at: Annales de Biologie Clinique.
Fazakas, Á., Szelényi, Z., Szénási, G., Nyírő, G., Szabó, P.M., Patócs, A., Tegze, N., Fekete, B.C., Molvarec, A., and Nagy, B. (2016). Genetic predisposition in patients with hypertension and normal ejection fraction to oxidative stress. Journal of the American Society of Hypertension 10, 124-132.
Friedrich, F.W., Dilanian, G., Khattar, P., Juhr, D., Gueneau, L., Charron, P., Fressart, V., Vilquin, J.T., Isnard, R., and Gouya, L. (2013). A novel genetic variant in the transcription factor Islet‐1 exerts gain of function on myocyte enhancer factor 2C promoter activity. European journal of heart failure 15, 267-276.
Ganna, A., Rivadeneira, F., Hofman, A., Uitterlinden, A.G., Magnusson, P.K., Pedersen, N.L., Ingelsson, E., and Tiemeier, H. (2013). Genetic determinants of mortality. Can findings from genome-wide association studies explain variation in human mortality? Human genetics 132, 553-561.
Grassi, D., Ferri, L., Desideri, G., Di Giosia, P., Cheli, P., Del Pinto, R., Properzi, G., and Ferri, C. (2013). Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Current pharmaceutical design 19, 2432-2438.
Hage, C., Michaëlsson, E., Linde, C., Donal, E., Daubert, J.-C., Gan, L.-M., and Lund, L.H. (2017). Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Genetics 10, e001633.
Hayashida, K., Kondo, Y., Hara, Y., Aihara, M., and Yamakawa, K. (2017). Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis. BMJ open 7, e014305.
Hershberger, R.E., and Siegfried, J.D. (2011). Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57, 1641-1649.
Hofman, N., van Langen, I., and Wilde, A.A. (2010). Genetic testing in cardiovascular diseases. Current opinion in cardiology 25, 243-248.
Huerta, A., López, B., Ravassa, S., San José, G., Querejeta, R., Beloqui, Ó., Zubillaga, E., Rábago, G., Brugnolaro, C., and Díez, J. (2016). Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. Journal of hypertension 34, 130-138.
Hutchinson, K.R., Stewart, J.A., and Lucchesi, P.A. (2010). Extracellular matrix remodeling during the progression of volume overload-induced heart failure. Journal of molecular and cellular cardiology 48, 564-569.
Imran, T.F., Shin, H.J., Mathenge, N., Wang, F., Kim, B., Joseph, J., Gaziano, J.M., and Djoussé, L. (2017). Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. The American Journal of Cardiology 119, 57-64.
Jansen, F., Nickenig, G., and Werner, N. (2017). Extracellular Vesicles in Cardiovascular Disease. Circulation research 120, 1649-1657.
Kang, S., Fan, L., Chen, M., Li, J., and Liu, Z. (2017). Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure. Current vascular pharmacology, 10.2174/1570161115666170404121619.
Kempf, T., and Wollert, K.C. (2009). Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34, 594-599.
Kim, H., Yoon, H.J., Park, H.S., Cho, Y.K., Nam, C.W., Hur, S.H., Kim, Y.N., and Kim, K.B. (2013). Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congestive Heart Failure 19, 123-129.
Kim, T.-H., Kim, H., and Kim, I.-C. (2015). The potential of cystatin-C to evaluate the prognosis of acute heart failure: A comparative study. Acute Cardiac Care 17, 72-76.
Kitai, T., Kim, Y.-H., Kiefer, K., Morales, R., Borowski, A.G., Grodin, J.L., and Tang, W.W. (2017). Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clinical Biochemistry 50, 491-495.
Kolder, I.C., Michels, M., Christiaans, I., Ten Cate, F.J., Majoor-Krakauer, D., Danser, A.H., Lekanne Deprez, R.H., Tanck, M., Wilde, A.A., Bezzina, C.R., et al. (2012). The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. European journal of human genetics : EJHG 20, 1071-1077.
Krane, V., Genser, B., Kleber, M.E., Drechsler, C., März, W., Delgado, G., Allolio, B., Wanner, C., and Fenske, W. (2017). Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study. Clinical Chemistry 63, 997-1007.
Krintus, M., Kozinski, M., Fabiszak, T., Kubica, J., Panteghini, M., and Sypniewska, G. (2017). Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry 50, 599-604.
Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., and Patle, A. (2013). Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. Jama 310, 66-74.
Li, J., Yousefi, K., Ding, W., Singh, J., and Shehadeh, L.A. (2017). Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure. Cardiovascular research 113, 633-643.
Löfsjögård, J., Kahan, T., Díez, J., López, B., González, A., Ravassa, S., Mejhert, M., Edner, M., and Persson, H. (2017). Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients≥ 60 Years With Heart Failure and Reduced Ejection Fraction. The American Journal of Cardiology 119, 2042-2048.
Löfsjögård, J., Persson, H., Díez, J., López, B., González, A., Edner, M., Mejhert, M., and Kahan, T. (2014). Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. Scandinavian Cardiovascular Journal 48, 299-303.
Lopes, L.R., and Elliott, P.M. (2013). Genetics of heart failure. Biochimica et biophysica acta 1832, 2451-2461.
Luchner, A., Von Haehling, S., Holubarsch, C., Keller, T., Knebel, F., Zugck, C., and Laufs, U. (2017). Indications and Clinical Implications of the Use of the Cardiac Markers BNP and NT-proBNP. Deutsche medizinische Wochenschrift (1946) 142, 346.
Maisel, A.S., and Di Somma, S. (2016). Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). European Heart Journal, ehw462.
Malek, V., and Gaikwad, A.B. (2017). Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 90, 752-759.
Masson, S., Latini, R., and Anand, I.S. (2010). An update on cardiac troponins as circulating biomarkers in heart failure. Current heart failure reports 7, 15-21.
McNamara, D.M., Taylor, A.L., Tam, S.W., Worcel, M., Yancy, C.W., Hanley-Yanez, K., Cohn, J.N., and Feldman, A.M. (2014). G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. JACC: Heart Failure 2, 551-557.
Meijers, W.C., van der Velde, A.R., Muller Kobold, A.C., Dijck‐Brouwer, J., Wu, A.H., Jaffe, A., and de Boer, R.A. (2016). Variability of biomarkers in patients with chronic heart failure and healthy controls. European Journal of Heart Failure 19, 357-365.
Miró, Ò., González de la Presa, B., Herrero-Puente, P., Fernández Bonifacio, R., Möckel, M., Mueller, C., Casals, G., Sandalinas, S., Llorens, P., and Martín-Sánchez, F.J. (2017). The GALA study: relationship between galectin-3 serum levels and short-and long-term outcomes of patients with acute heart failure. Biomarkers, 10.1080/1354750X.1352017.1319421.
Moayedi, Y., and Ross, H.J. (2017). Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clinical science (London, England : 1979) 131, 553-566.
Morgenthaler, N.G., Struck, J., Alonso, C., and Bergmann, A. (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical chemistry 52, 112-119.
Nagarajan, V., Hernandez, A.V., and Tang, W.W. (2012). Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart, heartjnl-2012-301779.
Nakanishi, M., Nakao, K., Kumasaka, L., Arakawa, T., Fukui, S., Ohara, T., Yanase, M., Noguchi, T., Yasuda, S., and Goto, Y. (2017). Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level. Circulation Journal, CJ-16-1268.
Nelveg-Kristensen, K.E., Busk Madsen, M., Torp-Pedersen, C., Kober, L., Egfjord, M., Berg Rasmussen, H., and Riis Hansen, P. (2015). Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study. PloS one 10, e0144195.
Nymo, S.H., Aukrust, P., Kjekshus, J., McMurray, J.J., Cleland, J.G., Wikstrand, J., Muntendam, P., Wienhues-Thelen, U., Latini, R., Askevold, E.T., et al. (2017). Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. JACC Heart failure 5, 256-264.
Okazaki, H., Shirakabe, A., Kobayashi, N., Hata, N., Shinada, T., Matsushita, M., Yamamoto, Y., Shibata, Y., Shibuya, J., Shiomura, R., et al. (2017). Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart and Vessels 32, 436-445.
Okazaki, H., Shirakabe, A., Kobayashi, N., Hata, N., Shinada, T., Matsushita, M., Yamamoto, Y., Shibuya, J., Shiomura, R., and Nishigoori, S. (2016). The prognostic impact of uric acid in patients with severely decompensated acute heart failure. Journal of cardiology 68, 384-391.
Otaki, Y., Watanabe, T., Kinoshita, D., Yokoyama, M., Takahashi, T., Toshima, T., Sugai, T., Murase, T., Nakamura, T., and Nishiyama, S. (2017). Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. International Journal of Cardiology 228, 151-157.
Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., Falk, V., González-Juanatey, J.R., Harjola, V.-P., and Jankowska, E.A. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal 37, 2129-2200.
Pouleur, A.-C. (2015). Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? Clinica Chimica Acta 443, 9-16.
Puente, P.H., García, B.P., García, M.G., Jacob, J., Martín-Sánchez, F.J., Pascual-Figal, D., Bueno, H., Gil, V., Llorens, P., and Vázquez-Alvarez, J. (2017). Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency department for acute heart failure. BIO-EAHFE study. Clinica Chimica Acta 466, 22-30.
Qian, H.-Y., Huang, J., Yang, Y.-J., Yang, Y.-M., Li, Z.-Z., and Zhang, J.-M. (2016). Heart-type Fatty Acid Binding Protein in the Assessment of Acute Pulmonary Embolism. The American Journal of the Medical Sciences 352, 557-562.
Reiner, M.M., Khoury, W.E., Canales, M.B., Chmielewski, R.A., Patel, K., Razzante, M.C., Cloughtery, C.O., and Rowland, D.Y. (2017). Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections. The Journal of Foot and Ankle Surgery 56, 484-491.
Remde, H., Dietz, A., Emeny, R., Riester, A., Peters, A., de Las Heras Gala, T., Then, C., Seissler, J., Beuschlein, F., Reincke, M., et al. (2016). The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. Journal of hypertension 34, 2066-2073.
Rienks, M., and Papageorgiou, A.-P. (2016). Novel regulators of cardiac inflammation: matricellular proteins expand their repertoire. Journal of molecular and cellular cardiology 91, 172-178.
Ryu, J.A., Yang, J.H., Lee, D., Park, C.M., Suh, G.Y., Jeon, K., Cho, J., Baek, S.Y., Carriere, K.C., and Chung, C.R. (2015). Clinical Usefulness of Procalcitonin and C-Reactive Protein as Outcome Predictors in Critically Ill Patients with Severe Sepsis and Septic Shock. PloS one 10, e0138150.
Sahin, I., Gungor, B., Ozkaynak, B., Uzun, F., Küçük, S.H., Avci, I.I., Ozal, E., Ayça, B., Cetın, S., and Okuyan, E. (2016). Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy. Clinical Cardiology 40, 32-37.
Sakamuri, S.S., Takawale, A., Basu, R., Fedak, P.W., Freed, D., Sergi, C., Oudit, G.Y., and Kassiri, Z. (2016). Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure. Translational Research 172, 30-44.
Savic-Radojevic, A., Pljesa-Ercegovac, M., Matic, M., Simic, D., Radovanovic, S., and Simic, T. (2017). Chapter Four-Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry 79, 93-152.
Simon, L., Gauvin, F., Amre, D.K., Saint-Louis, P., and Lacroix, J. (2004). Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clinical infectious diseases 39, 206-217.
Smaradottir, M.I., Ritsinger, V., Gyberg, V., Norhammar, A., Näsman, P., and Mellbin, L.G. (2017). Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities–A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diabetes and Vascular Disease Research 14, 69-76.
Srivatsan, V., George, M., and Shanmugam, E. (2015). Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? European journal of preventive cardiology 22, 1096-1110.
Sutter, M.E., Gaedigk, A., Albertson, T.E., Southard, J., Owen, K.P., Mills, L.D., and Diercks, D.B. (2013). Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clinical toxicology (Philadelphia, Pa) 51, 540-544.
Taub, P.R., Borden, K.C., Fard, A., and Maisel, A. (2012). Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert review of cardiovascular therapy 10, 657-667.
Teekakirikul, P., Kelly, M.A., Rehm, H.L., Lakdawala, N.K., and Funke, B.H. (2013). Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. The Journal of Molecular Diagnostics 15, 158-170.
Teo, L.Y.L., Moran, R.T., and Tang, W.W. (2015). Evolving approaches to genetic evaluation of specific cardiomyopathies. Current heart failure reports 12, 339-349.
Tromp, J., Khan, M.A., Klip, I.T., Meyer, S., de Boer, R.A., Jaarsma, T., Hillege, H., van Veldhuisen, D.J., van der Meer, P., and Voors, A.A. (2017). Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American Heart Association 6, e003989.
Tziakas, D.N., Chalikias, G.K., Stakos, D., Chatzikyriakou, S.V., Papazoglou, D., Mitrousi, K., Lantzouraki, A., Thomaidi, A., Boudoulas, H., and Konstantinides, S. (2012). Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. European journal of preventive cardiology 19, 62-71.
Valiente-Alandi, I., Schafer, A.E., and Blaxall, B.C. (2016). Extracellular matrix-mediated cellular communication in the heart. Journal of molecular and cellular cardiology 91, 228-237.
Wettersten, N., and Maisel, A.S. (2016). Biomarkers for heart failure: An update for practitioners of internal medicine. The American journal of medicine 129, 560-567.
Wojciechowska, C., Romuk, E., Nowalany-Kozielska, E., and Jacheć, W. (2017). Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic Journal of Cardiology S1109-9666, 30249-30244.
Wong, P.C., Guo, J., and Zhang, A. (2017). The renal and cardiovascular effects of natriuretic peptides. Advances in physiology education 41, 179-185.
Wu, C.K., Luo, J.L., Tsai, C.T., Huang, Y.T., Cheng, C.L., Lee, J.K., Lin, L.Y., Lin, J.W., Hwang, J.J., and Chiang, F.T. (2010). Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The pharmacogenomics journal 10, 46-53.
Wu, C.K., Luo, J.L., Wu, X.M., Tsai, C.T., Lin, J.W., Hwang, J.J., Lin, J.L., Tseng, C.D., and Chiang, F.T. (2009). A propensity score-based case-control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. Atherosclerosis 205, 497-502.
Yan, J.J., Lu, Y., Kuai, Z.P., and Yong, Y.H. (2017). Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta‐analysis. Journal of Cellular and Molecular Medicine, 10.1111/jcmm.13102.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Jr., Colvin, M.M., Drazner, M.H., Filippatos, G.S., Fonarow, G.C., Givertz, M.M., et al. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of cardiac failure, 10.1016/j.cardfail.2017.1004.1014.
Yang, J., Xu, W.W., and Hu, S.J. (2015). Heart failure: advanced development in genetics and epigenetics. BioMed research international 2015, 352734.
Yip, V.L., and Pirmohamed, M. (2013). Expanding role of pharmacogenomics in the management of cardiovascular disorders. American journal of cardiovascular drugs : drugs, devices, and other interventions 13, 151-162.
Yu, B., Zheng, Y., Alexander, D., Manolio, T.A., Alonso, A., Nettleton, J.A., and Boerwinkle, E. (2013). Genome-wide association study of a heart failure related metabolomic profile among African Americans in the Atherosclerosis Risk in Communities (ARIC) study. Genetic epidemiology 37, 840-845.
Zhu, L., Zou, Y., Wang, Y., Luo, X., Sun, K., Wang, H., Jia, L., Liu, Y., Zou, J., and Yuan, Z. (2017). Prognostic Significance of Plasma High‐Sensitivity C‐Reactive Protein in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association 6, e004529.
Downloads
Published
2017-06-24
Issue
Section
Review
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
How to Cite
Up-to-date clinical approaches of biomarkers’ use in heart failure. (2017). Biomedical Research and Therapy, 4(06), 1344-1373. https://doi.org/10.15419/bmrat.v4i06.178
